NASDAQ · XFOR
X4 Pharmaceuticals, Inc.
$3.36+$0.01 (+0.3%)
X4 Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 30.43% below the high.
Loading market information…
AMEX · CVM · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
CEL-SCI Corporation’s quoted price sits in the lower half of its reported 52-week range, 80.77% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
CEL-SCI Corporation’s next earnings report is currently expected on Dec 23, 2026. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow CEL-SCI Corporation’s reporting calendar.
THE COMPANY BEHIND THE TICKER
CEL-SCI Corporation (CVM) focuses on the research and development of immune-based therapies to combat cancer and various infectious diseases. Its flagship immunotherapy candidate, Multikine, is currently undergoing Phase III clinical trials for the treatment of head and neck cancer. The company also develops and holds the patent for its preclinical Ligand Epitope Antigen Presentation System (LEAPS), an innovative T-cell modulation technology. This system is designed to stimulate the human immune system to fight a broad range of conditions, including bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and various cancers. CEL-SCI's pipeline further includes LEAPS-H1N1-DC, along with LEAPS COV-19, an experimental therapy targeting the COVID-19 coronavirus. Additionally, the company is advancing CEL-2000 and CEL-4000 as potential treatments for rheumatoid arthritis. In a collaborative effort, CEL-SCI has partnered with the University of Georgia's Center for Vaccines and Immunology to progress the LEAPS COVID-19 immunotherapy. Established in 1983, the company's headquarters are located in Vienna, Virginia.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:31 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
THE ANALYST VIEW
6 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$3.36+$0.01 (+0.3%)
X4 Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 30.43% below the high.
$29.08$0.00 (0.0%)
Mersana Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 4.31% below the high.
$2.62-$0.01 (-0.38%)
OnKure Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 51.3% below the high.
$1.55+$0.03 (+1.97%)
PDS Biotechnology Corporation’s quoted price sits in the upper half of its reported 52-week range, 13.41% below the high.
$7.29$0.00 (0.0%)
Kezar Life Sciences, Inc.’s quoted price sits in the upper half of its reported 52-week range, 3.44% below the high.
$1.60+$0.07 (+4.58%)
INmune Bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 38.46% below the high.
$9.07-$0.15 (-1.63%)
FibroGen, Inc.’s quoted price sits in the lower half of its reported 52-week range, 58.68% below the high.
$5.03-$0.14 (-2.71%)
Aligos Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 63.26% below the high.
